Evidence map›Paper›PMID 41620527›Full record

ArticleNPJ digital medicine2026

Challenges in applying the EU AI act research exemptions to contemporary AI research.

Janos Meszaros, Isabelle Huys, John P A Ioannidis

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Janos MeszarosClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, KU Leuven, Belgium. janos.meszaros@kuleuven.be.
Isabelle HuysClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, KU Leuven, Belgium.
John P A IoannidisMeta-Research Innovation Center at Stanford (METRICS) and Departments of Medicine, of Epidemiology and Population Health, and Biomedical Data Science, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EU Artificial Intelligence Act (AI Act) is the world's first comprehensive, cross-sectoral legal framework dedicated specifically to AI. It introduces a structured regulatory approach to ensure that AI systems are safe, transparent, and trustworthy. To foster innovation, it includes research exemptions that place certain AI systems - those under development or used solely for scientific research - outside of its scope and obligations. However, this paper argues that these exemptions rely on distinctions that may not fully capture the realities of contemporary AI research. These include the unclear divide between research and commercial activities, and between lab-based development and real-world testing. Through legal analysis and practical scenarios, we demonstrate how the blurred boundaries between academic and commercial interests, as well as between controlled research and real-world use, create regulatory uncertainty and open the door to potential misuse. The paper highlights the risks stemming from vague definitions and the lack of harmonized guidance. It ultimately calls for clearer guidance, stronger safeguards, and more realistic frameworks that reflect the complexities of modern AI research.

Identifiers

PMID41620527
PMCPMC13057238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.